Supernus Pharmaceuticals (SUPN) Operating Leases (2019 - 2026)

Supernus Pharmaceuticals (SUPN) has 8 years of Operating Leases data on file, last reported at $40.9 million in Q1 2026.

• On a quarterly basis, Operating Leases rose 55.12% year-over-year to $40.9 million in Q1 2026; TTM through Mar 2026 was $40.9 million, a 55.12% increase from a year earlier, with the FY2025 full-year figure at $41.0 million, up 19.57% from the prior year.
• Operating Leases for Q1 2026 stood at $40.9 million, roughly flat from $41.0 million in the prior quarter.
• Over the last five years, Operating Leases for SUPN reached as high as $46.0 million in Q1 2022 and fell as low as $24.4 million in Q2 2025.
• Historically, Operating Leases has averaged $36.7 million across 5 years, with a median of $36.0 million in 2022.
• Across the five-year window, Operating Leases jumped 61.33% in 2022 and declined 28.21% in 2024, its largest moves.
• Year by year, Operating Leases stood at $36.0 million in 2022, then gained by 15.36% to $41.5 million in 2023, then declined by 17.47% to $34.3 million in 2024, then increased by 19.57% to $41.0 million in 2025, then dropped by 0.18% to $40.9 million in 2026.
• Per Business Quant data, the three most recent Operating Leases figures were $40.9 million in Q1 2026, $41.0 million in Q4 2025, and $31.4 million in Q3 2025.